Actively Recruiting
Study Comparing Different Durations of Sulfamethoxazole to Prevent Pneumocystis Jirovecii Pneumonia After Kidney Transplant
Led by Anhui Provincial Hospital · Updated on 2025-12-16
450
Participants Needed
1
Research Sites
75 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to determine the best duration for using trimethoprim-sulfamethoxazole TMP-SMX to prevent Pneumocystis jirovecii pneumonia PJP in patients after kidney transplantation. PJP is a common and serious lung infection that can occur after renal transplantation, affecting patient survival. Although TMP-SMX is the preferred drug to prevent PJP, the ideal length of treatment is unclear, with current guidelines varying from 6 to 12 months. This study also explores the relationship between drug levels in the blood and PJP occurrence or side effects to improve prevention strategies. The trial will enroll 450 kidney transplant patients who will be randomly assigned to one of three groups receiving TMP-SMX prophylaxis for 6, 12, or 18 months. This single-center, randomized, controlled study compares the effects of these different treatment durations on PJP prevention. Researchers will monitor patients during and after treatment to assess outcomes and optimize dosing. Participants will be followed up for 18 months after treatment ends. During this time, the main focus will be on tracking the incidence of PJP and any adverse reactions. Blood tests will measure drug levels to help develop a clinical model guiding effective TMP-SMX dosing. The study aims to provide clearer recommendations to reduce PJP rates and improve kidney transplant patient care.
CONDITIONS
Brief Title
Sulfamethoxazole Prophylaxis Duration After Renal Transplantation
Research Team
X
Xuqin Jiang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here